Martin Zapata Laguado, Clinical Oncologist at Instituto Nacional de Cancerología in Bogotá, shared on X:
“EMUC26 Prosp ph II study (n=22) in MIBC:
Ga-FAPI PET/MRI showed similar staging accuracy to ¹⁸F-FDG PET/CT. Both had moderate sensitivity and high specificity, limiting their ability to rule out disease.”
EMUC26 Nectin-4 PET:
An emerging imaging strategy for urothelial cancer. Nectin-4 is expressed in ~87% of UC tumors, a key target of enfortumab vedotin. Could Nectin-4 PET improve staging and guide targeted therapy?
You can also read:
OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition Part 2